High-tech light
High-tech light

Development Path

2022

·Zhejiang Dongyang Base started construction with a total investment of not less than 5 billion
·Low-carbon high-end battery aluminum foil project started construction in Yichang, Hubei

2021

·HEC Pharmaceutical Research Institute completed A round of financing of nearly 7 billion yuan
·HEC Pharmaceutical Research Institute completed the equity control of HEC Pharmaceutical (01558.HK), realizing the integration of pharmaceutical assets

2020

·Mr. Zhang Yushuai took over as chairman of HEC Group and established a new board of directors of HEC Group. HEC officially entered the 2.0 new era of "co-creation, co-responsibility and sharing"
·HEC's first Class 1.1 original innovative drug "Emitasvir Phosphate" was approved for marketing

2019

The annual sales of anti-influenza drug Kewei reached nearly 7 billion yuan, setting a new high for similar anti-influenza drug products in China

2018

·Cordyceps sinensis (breeding product) was included in "Guangdong Province Local Medicinal Materials Standard" (Volume 3)
·"Research on key technologies of Cordyceps sinensis breeding and its industrial application" won the first prize of Guangdong Science and Technology Progress Award

2017

The construction of the Ulanchap base in Inner Mongolia started with an investment of nearly 2 billion yuan

2016

HEC Health Research Institute was approved by the State Administration of Traditional Chinese Medicine to establish the "Key Research Laboratory of Cordyceps Sinensis Breeding and Product Research and Development"

2015

·HEC Pharma was listed on the main board of Hong Kong, stock code: 01558.HK
·HEC Pharmaceutical Research Institute is approved by the Ministry of Science and Technology of the People's Republic of China to establish a "State Key Laboratory of New Anti-infective Drug Research and Development"

2014

The construction of the Nyingchi base in Tibet began, which is a supporting base for the ecological breeding of Cordyceps sinensis

2013

A-share listed company HEC (600673.SH) issued additional private placements to expand the medium and high pressure formed foil project and the high specific volume corrosion foil project

2012

Took the lead in realizing the industrialization of Cordyceps sinensis ecological breeding in the world

2011

HEC's first generic drug approved by the U.S. FDA, Zidovudine Tablets for the treatment of AIDS, was on the market

2010

Shaoguan started the construction of pharmaceutical industry projects

2009

Provided oseltamivir phosphate reserve drug for the country's prevention and control of influenza epidemic, and commended by the National Development and Reform Commission

2008

Started the process of internationalization of preparations

2007

New electronic material assets were injected into A-share listed company HEC (600673.SH)

2006

Obtained the exclusive authorization of Roche's "Oseltamivir Phosphate"

2005

HEC a comprehensive and systematic research institute was established

2004

Zunyi Base in Guizhou  started construction

2003

·HEC A-share backdoor listing, stock code: 600673.SH
·Dongguan Songshan Lake Factory started construction

2002

·Guangdong Dongguan Base started construction
·Acquired Hubei Changhe Pharmaceutical Co., Ltd. and officially entered the pharmaceutical industry

2001

Yichang base in Hubei started construction

2000

"Low-voltage and high-volume formed foil" was included in the "Double High and One Excellent" project-oriented plan of the State Economic and Trade Commission's national key technological transformation

1999

HEC fully implemented the management of the general outline system, and the first edition of the "Outline of Work" was officially published and released

1998

The construction of Shaoguan base in Guangdong began, focusing on the development of electronic materials industry

1997

Mr. Zhang Zhongneng founded HEC Group